생체재료학회지 (Biomaterials Research)

  • 제22권2호
  • /
  • Pages.150-157
  • /
  • 2018
  • /
  • 1226-4601(pISSN)
  • /
  • 2055-7124(eISSN)
한국생체재료학회 (Korean Society for Biomaterials)
권호 표지
DOI QR코드

DOI QR Code

Synthesis of a gadolinium based-macrocyclic MRI contrast agent for effective cancer diagnosis

  • Jeong, Yohan (Department of Biotechnology, The Catholic University of Korea) ;
  • Na, Kun (Department of Biotechnology, The Catholic University of Korea)
  • 투고 : 2018.03.29
  • 심사 : 2018.06.01
  • 발행 : 2018.06.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Gadolinium-based contrast agents are widely used as a contrast agent for magnetic resonance imaging. Since gadolinium ions are toxic, many chelators are developed to bind gadolinium ions to prevent free gadolinium-associated disease. However, many reports indicated that linear chelator-based contrast agents are associated with nephrogenic systemic fibrosis (NSF) in patients with low kidney function. Therefore, the demand for stable macrocyclic chelator-based contrast agent is now increasing. Method: 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetate (DOTA) was conjugated to lactobionic acid (LBA) through DCC-NHS coupling reaction. $Gd^{3+}$ (gadolinium ion) was chelated to 1,4,7,10-Tetraazacyclododecane1,4,7,10-tetraacetate-lactobionic acid (DOTA-LAE) and free $Gd^{3+}$ was removed using a cation exchange column. In vitro cytotoxicity of contrast agent towards normal cells was measured using MTT assay. For in vivo MR imaging, contrast agents were intravenously injected to tumor-bearing mice and imaged by a MR imaging scanner. Results: This new macrocyclic gadolinium-based contrast agent showed enhanced in vitro paramagnetic properties compared to Gadovist. In addition, Gd-DOTA-LAE showed a 29% increased contrast enhancement of tumor tissue compared to normal tissue within 20 min past IV injection. Conclusions: We developed a new macrocyclic T1-weighted MR contrast agent. This new contrast agent offers various opportunities for cancer detection and diagnosis.

키워드

참고문헌

  1. Jaffer FA, Weissleder R. Molecular imaging in the clinical arena. JAMA. 2005; 293:855-62. https://doi.org/10.1001/jama.293.7.855
  2. Koh D-M, Cook GJ, Husband JE. New horizons in oncologic imaging. N Engl J Med. 2003;348:2487-8. https://doi.org/10.1056/NEJMp030048
  3. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium (III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99: 2293-352. https://doi.org/10.1021/cr980440x
  4. Li Y, Beija M, Laurent S, Elst LV, Muller RN, Duong HT, Lowe AB, Davis TP, Boyer C. Macromolecular ligands for gadolinium MRI contrast agents. Macromolecules. 2012;45:4196-204. https://doi.org/10.1002/chem.200204612
  5. Lim J, Turkbey B, Bernardo M, Bryant LH Jr, Garzoni M, Pavan GM, Nakajima T, Choyke PL, Simanek EE, Kobayashi H. Gadolinium MRI contrast agents based on triazine dendrimers: relaxivity and in vivo pharmacokinetics. Bioconjug Chem. 2012;23:2291-9. https://doi.org/10.1021/bc300461r
  6. Raymond KN, Pierre VC. Next generation, high relaxivity gadolinium MRI agents. Bioconjug Chem. 2005;16:3-8. https://doi.org/10.1021/bc049817y
  7. Hooker JM, Datta A, Botta M, Raymond KN, Francis MB. Magnetic resonance contrast agents from viral capsid shells: a comparison of exterior and interior cargo strategies. Nano Lett. 2007;7:2207-10. https://doi.org/10.1021/nl070512c
  8. Song Y, Xu X, MacRenaris KW, Zhang XQ, Mirkin CA, Meade TJ. Multimodal gadolinium-enriched DNA-gold nanoparticle conjugates for cellular imaging. Angew Chem Int Ed. 2009;48:9143-7. https://doi.org/10.1002/anie.200904666
  9. Ward K, Aletras A, Balaban RS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J Magn Reson. 2000;143:79-87. https://doi.org/10.1006/jmre.1999.1956
  10. Werner EJ, Datta A, Jocher CJ, Raymond KN. High-relaxivity MRI contrast agents: where coordination chemistry meets medical imaging. Angew Chem Int Ed. 2008;47:8568-80. https://doi.org/10.1002/anie.200800212
  11. Chen W, Vucic E, Leupold E, Mulder WJ, Cormode DP, Briley-Saebo KC, Barazza A, Fisher EA, Dathe M, Fayad ZA. Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging. 2008;3:233-42. https://doi.org/10.1002/cmmi.257
  12. Corot C, Robert P, Lancelot E, Prigent P, Ballet S, Guilbert I, Raynaud JS, Raynal I, Port M. Tumor imaging using P866, a high-relaxivity gadolinium chelate designed for folate receptor targeting. Magn Reson Med. 2008;60: 1337-46. https://doi.org/10.1002/mrm.21773
  13. Kim KS, Park W, Hu J, Bae YH, Na K. A cancer-recognizable MRI contrast agents using pH-responsive polymeric micelle. Biomaterials. 2014;35:337-43. https://doi.org/10.1016/j.biomaterials.2013.10.004
  14. Konda SD, Aref M, Wang S, Brechbiel M, Wiener EC. Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. MAGMA. 2001;12:104-13. https://doi.org/10.1007/BF02668091
  15. Shu C-Y, Ma X-Y, Zhang J-F, Corwin FD, Sim JH, Zhang E-Y, Dorn HC, Gibson HW, Fatouros PP, Wang C-R. Conjugation of a water-soluble gadolinium endohedral fulleride with an antibody as a magnetic resonance imaging contrast agent. Bioconjug Chem. 2008;19:651-5. https://doi.org/10.1021/bc7002742
  16. Yim H, Yang S-G, Jeon YS, Park IS, Kim M, Lee DH, Bae YH, Na K. The performance of gadolinium diethylene triamine pentaacetate-pullulan hepatocyte-specific T1 contrast agent for MRI. Biomaterials. 2011;32:5187-94. https://doi.org/10.1016/j.biomaterials.2011.03.069
  17. Datta A, Raymond KN. Gd-hydroxypyridinone (HOPO)-based high-relaxivity magnetic resonance imaging (MRI) contrast agents. Acc Chem Res. 2009;42: 938-47. https://doi.org/10.1021/ar800250h
  18. Pierre VC, Botta M, Raymond KN. Dendrimeric gadolinium chelate with fast water exchange and high relaxivity at high magnetic field strength. J Am Chem Soc. 2005;127:504-5. https://doi.org/10.1021/ja045263y
  19. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-8. https://doi.org/10.1093/ndt/gfk062
  20. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology. 2007;242:647-9. https://doi.org/10.1148/radiol.2423061640
  21. Thomson LK, Thomson PC, Kingsmore DB, Blessing K, Daly CD, Cowper SE, Roditi GH. Diagnosing nephrogenic systemic fibrosis in the post-FDA restriction era. J Magn Reson Imaging. 2015;41:1268-71. https://doi.org/10.1002/jmri.24664
  22. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis. 2005;46:754-9. https://doi.org/10.1053/j.ajkd.2005.06.024
  23. Thomsen HS, Morcos SK, Almen T, Bellin M-F, Bertolotto M, Bongartz G, Clement O, Leander P, Heinz-Peer G, Reimer P. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR contrast medium safety committee guidelines. Eur Radiol. 2013;23:307-18. https://doi.org/10.1007/s00330-012-2597-9
  24. Grogna M, Cloots R, Luxen A, Jerome C, Desreux J-F, Detrembleur C. Design and synthesis of novel DOTA (Gd 3+)-polymer conjugates as potential MRI contrast agents. J Mater Chem. 2011;21:12917-26. https://doi.org/10.1039/C1JM00005E
  25. Barge A, Cravotto G, Gianolio E, Fedeli F. How to determine free Gd and free ligand in solution of Gd chelates. A technical note. Contrast Media Mol Imaging. 2006;1:184-8. https://doi.org/10.1002/cmmi.110

피인용 문헌

  1. Application of black phosphorus nanodots to live cell imaging vol.22, pp.1, 2018, https://doi.org/10.1186/s40824-018-0142-x
  2. Fluorinated MRI contrast agents and their versatile applications in the biomedical field vol.11, pp.10, 2018, https://doi.org/10.4155/fmc-2018-0463
  3. The Transition from Metal-Based to Metal-Free Contrast Agents for T1 Magnetic Resonance Imaging Enhancement vol.30, pp.9, 2019, https://doi.org/10.1021/acs.bioconjchem.9b00499
  4. Magnetic nanoparticles applied in targeted therapy and magnetic resonance imaging: crucial preparation parameters, indispensable pre-treatments, updated research advancements and future perspectives vol.8, pp.28, 2020, https://doi.org/10.1039/d0tb00552e
  5. A Gadolinium DO3A Amide m-Phenyl Boronic Acid MRI Probe for Targeted Imaging of Sialated Solid Tumors vol.9, pp.10, 2018, https://doi.org/10.3390/biomedicines9101459
  6. Influence of polyethylene glycol on the physical properties of Co0.2Fe2.8O4 nanoparticles used as MRI contrast agent; synchrotron radiation Fe K-edge XAFS vol.15, pp.None, 2018, https://doi.org/10.1016/j.jmrt.2021.09.143